By Fineline Cube 
China’s Harbin Pharmaceutical Group Holding Co., Ltd (SHA: 600664) announced a technology transfer agreement with Shanghai Bocimed Pharmaceutical Research Co., Ltd, a compatriot firm specializing in diversified drug delivery technologies. The deal involves total payments of RMB 44.8 million (USD 6.2 million).
Agreement Details
Under the agreement, Harbin Pharma will acquire clinical approval for Bocimed Pharm’s generic version of GSK’s Jesduvroq (daprodustat), a hypoxia-inducible factor–prolyl hydroxylase inhibitor (HIF-PHI) used to treat anemia associated with chronic kidney disease (CKD). Harbin Pharma will also entrust Bocimed Pharm to continue providing follow-up generic drug research and development services until the drug receives marketing approval.
Jesduvroq’s Regulatory Status
Jesduvroq was approved in Japan in 2020 and in the US in 2023 but has not yet received marketing clearance in China. This collaboration aims to advance the drug’s development and regulatory approval in the Chinese market.-Fineline Info & Tech